G. J. G  K. A. G. ATP-Sensitive Potassium Channels: A Review of their Cardioprotective Pharmacology. Journal of Molecular and Cellular Cardiology (2000) 32, 677-696. ATP-sensitive potassium channels (K ATP ) have been thought to be a mediator of cardioprotection for the last ten years. Significant progress has been made in learning the pharmacology of this channel as well as its molecular regulation with regard to cardioprotection. K ATP openers as a class protect ischemic/reperfused myocardium and appear to do so by conservation of energy. The reduced rate of ATP hydrolysis during ischemia exerted by these openers is not due to a cardioplegic effect and is independent of action potential shortening. Compounds have been synthesized which retain the cardioprotective effects of first generation K ATP openers, but are devoid of vasodilator and cardiac sarcolemmal potassium outward currents. These results suggest receptor or channel subtypes. Recent pharmacologic and molecular biology studies suggest the activation of mitochondrial K ATP as the relevant cardioprotective site. Implications of these results for future drug discovery and preconditioning are discussed.
Introduction
peutic potential of K ATP for the treatment of acute myocardial ischemia. Recently several lines of investigation concerning ATP-sensitive potassium channels (K ATP ) have conRecent studies have further fueled interest in K ATP by suggesting differential importance of K ATP verged, suggesting that K ATP may be an important therapeutic target for the treatment of acute myosubtypes. These studies show that cardioprotection may not be mediated by sarcolemmal K ATP currents, cardial ischemia. Pharmacologic studies starting in 1989 showed K ATP openers to exert profound suggesting an intracellular site of action (mitochondria). Therefore, it is possible to develop agents cardioprotective effects in numerous mammalian species. The results of this work were made even which can selectively open the K ATP subtype of interest. more relevant by later findings showing preconditioning to be mediated (at least in part) by
With the heightened interest created by the studies described above, it would be useful to review K ATP activation. Therefore, pharmacologic K ATP activation would be expected to mimic an endogenous what is presently known about K ATP , particularly the recent insights into the molecular biology and cardioprotective mechanism that also seems to be operative in man. These converging results have regulation of these channels and how these findings can help us understand their cardioprotective pharhyperpolarize or depolarize pancreatic -cells respectively. 11, 12 These channels are important for macology. We will place some emphasis on the newly hypothesized role of mitochondrial channels setting membrane potential in pancreatic -cells and the closure of a few channels (as seen by an in cardioprotection. In this review, our heightened knowledge of the nature of the molecular regulation increase in extracellular glucose) will depolarize these cells and therefore stimulate insulin seof K ATP will be integrated with pharmacologic and physiologic studies so that the reader can better cretion. 13,14 Sulfonylurea K ATP blockers such as glibenclamide (glyburide) have utility for treating type understand the complex matrix of studies leading to our preset understanding of the role of K ATP II diabetes and increase insulin secretion by depolarizing -cell membranes. Opening of K ATP in and pharmacologic modulators of this channel in myocardial ischemia.
smooth muscle cells would be expected to hyperpolarize sarcolemmal membranes and therefore cause relaxation. 15 Most K ATP openers are potent vasodilators and smooth muscle relaxants and their earliest proposed clinical uses were asthma, hyper-
Properties and Molecular Biology of
tension, and urinary incontinence. The role of K ATP Plasma Membrane K ATP in normal myocardium is presently unclear, although a role in ischemic conditions is well known K ATP were first described by Noma 1 in cardiac ventricular myocytes. These channels are of interand will be discussed in full detail in this review. Opening cardiac K ATP will, of course, enhance a mediate conductance and are inhibited by physiologic concentrations of ATP. K ATP were orirepolarizing potassium current and therefore cause action potential duration (APD) shortening. 16 K ATP ginally termed ATP-dependent potassium channels because ATP was the first modulator studied, alare thought to be involved with the early repolarization seen in ischemic cardiac tissue. [17] [18] [19] This though other endogenous modulators have since been found and therefore they are now referred to early repolarization is associated with the "injury current" of ischemia which is the basis for STas "ATP-sensitive" channels. K ATP are inhibited by physiologic levels of ATP and, as ATP falls, channel segment shifts and it is thought that K ATP contribute, at least in part, to this electrophyiologic abopen probability increases (although the degree of ATP reduction needed would rarely be seen under normality.
17,20
K ATP is a complex of two different proteins.
21-23 physiologic conditions; see review by Edwards and Weston 2
). K ATP have been found to be modulated One subunit is an inwardly-rectifying potassium channel (Kir) subunit and it is thought that four by pH, fatty acids, NO, SH-redox state, various nucleotides, G-proteins and various ligands (adof these combine to form the channel pore. Two types of Kir (Kir6.1 and Kir6.2) are thought to be enosine, acetylcholine, benzopyrans, cyanoguanidines, etc.). [2] [3] [4] [5] [6] Larsson et al. 7 showed that associated with K ATP at this time. The sulfonylurea receptor (SUR) is the protein which confers a regupancreatic K ATP are opened by long-chain acyl CoA esters, and Paucek and Garlid (unpublished results) latory role as well as sensitivity of the channel to pharmacologic agents and ATP. 22 SUR is a member have observed similar opening of cardiac sarcolemmal channels by acyl CoA esters. K ATP appear of the ATP-binding cassette protein superfamily, also called ABC transporters and is related to CFTR to be linked to the metabolic state of the cell and have therefore also been labeled as metabolicaly channels (cystic fibrosis transmembrane regulator, also glyburide inhibitable). 24 This ATP transporter, regulated channels. K ATP are expressed in numerous tissue types including skeletal muscle, brain, kidney, CFTR, releases ATP, which interacts with a purinergic receptor subtype which then opens chloride heart, pancreatic -cells, and smooth muscle.
1,2,8-10 K ATP are thought to serve as a link between metachannels. SUR is a related ATP permeant protein.
SUR1 is highly expressed in pancreatic -cells, while bolism and either secretory activity (insulin, brain) or electro-mechanical coupling in muscle. K ATP are SUR2 is highly expressed in cardiac and skeletal muscle cells. 25 It is unknown how many ways also found in the inner mitochondrial membrane, and these will be described in a later section.
these ) (see struc-ADP reduces the sensitivity of K ATP for ATP and therefore it has been proposed that the channel is tures in Fig. 1 ). The activation of K ATP is inhibited by increased ATP suggesting an interaction or commodulated by the ratio of these nucleotides. It is thought that ADP competes for the ATP binding petition at the ATP binding (inhibitory) site. The K ATP activating effects of the pharmacologic openers site and ADP without the presence of ATP inhibits channel activity, although another ADP site is are inhibited by glyburide, although this inhibition does not appear to be through displacement from thought to mediate weak agonist activity. This may be a nucleotide phosphate site which is also a common receptor site. The effects of openers and blockers of K ATP appear to be modulated by the stimulated by GDP.
It has been proposed that K ATP openers reduce metabolic state of the cell, with openers being more active under ischemic conditions and blockers such the affinity of ATP at the regulatory or inhibitory site. In addition to an inhibitory action of ATP, K ATP as glyburide being less active during ischemia.
19,35
Recent studies show tissue differences in the activity will "run-down" in the absence of ATP and it is thought that ATP can prime K ATP for opening.
26
of K ATP openers and blockers, suggesting K ATP subtypes which is consistent with the recent findings Only MgATP (but not free ATP) can reactivate the channel and non-hydrolyzable forms of ATP are on the molecular biology of these channels.
36,37
Therefore, the signaling systems involved with ineffective. This is thought to require phosphorylation and therefore, channel "run-down" K ATP modulation appear complex and as yet, a clear picture has not been elucidated. We have included may be mediated by channel dephosphorylation. It has been proposed that a complex balance of a schematic diagram for proposed modulatory pathways for K ATP (Fig. 2) . This diagram is to be conphosphorylation and dephosphorylation of tyrosine and serine/threonine residues can modulate K ATP sidered speculative, as not all investigators agree on some of the proposed pathways. activity, although much needs to be learned about this regulatory mechanism. 27 It is presently unclear whether dephosphorylation and phosphorylation are involved with the mechanism of run-down and reactivation by MgATP (see review by Hiraoka and 
Effects of Pharmacologic Modulators of

K ATP on Myocardial Ischemia
Occupation of the appropriate receptors associated with G-proteins releases GDP and enhances
Because of the metabolic regulation of K ATP and its possible contribution to ischemic injury currents, GTP binding. A number of ligands known to interact with G i increase K ATP open probability and include it was natural to presume a role for this channel in the pathogenesis of myocardial ischemia. A good meditors such as acetylcholine and adenosine. Ligands such as adenosine (through the A 1 receptor means for determination of the role of K ATP in ischemia was to use selective openers and blockers subtype) may also activate protein kinase C (PKC) and it is thought that PKC activates K ATP in ventof this channel in various models of ischemia. Before detailed studies in models of ischemia were ricular myocytes by reducing channel sensitivity to ATP at the inhibitory site. 29 Protein kinase A (PKA) completed, two schools of thought existed. In one school, K ATP blockers would be protective, not only may modulate K ATP activity and data suggest it is involved with K ATP opening induced by calcitonin in terms of cardioprotection, but also in terms of inhibition of arrhythmogenesis. Another school of K ATP openers would exert a cardioplegic action and protect by inhibiting energy utilization and conthought was that K ATP openers would be protective because of their ability to shorten APD (and also tractile function in a manner similar to L-type calcium channel blockers. This hypothesis led many inhibit ischemic depolarization) and therefore reduce calcium entry. This hypothesis presumed that scientists to label K ATP openers as "indirect calcium effect of cromakalim on the time to ischemic contracture in isolated rat hearts. The improved reperfusion flow observed for some openers was not necessary for protection and was most likely secondary to increased metabolic demand in the healthier tissue. In this study, we also found that ischemic depolarization was inhibited by K ATP openers, although it was difficult to know whether this was the mechanism of protection or a result of protection occuring before ischemic depolarization. Since the publication of these results, we have found levcromakalim (showing cardioprotection to be stereoselective), bimakalim, aprikalim, and P-1075 to protect isolated rat hearts with a similar profile of action. [40] [41] [42] Interestingly, these agents were protecting hearts at concentrations that did not exert significant negative inotropic effects, therefore distinguishing these agents from calcium channel blockers. function. This study was important in further showing cardioprotective effects for a K ATP opener, but also suggested an association between APD shortening and cardioprotection. These data, however, channel blockers". As we will see, this hypothesis was inadequate to explain the cardioprotective efcould not definitively prove a connection between cardioprotection and APD shortening. At this confects of K ATP openers.
The idea that K ATP might be involved in ischemia centration (10 ), pinacidil was certainly opening sarcolemmal K ATP . Also of interest in this study was was first suggested by studies on nicorandil although the role of K ATP in the protective effects of nicorandil their finding that pinacidil was more effective in shortening APD during ischemia in myocardium, was not fully appreciated at the time (this compound is also an NO donor). 38 As more information on K ATP a finding we were able to confirm later in an in vivo model of ischemia in dogs. 16 became available, we wanted to examine the role of K ATP in myocardial ischemia in more detail using Since these early studies, numerous investigators have shown cardioprotective effects for K ATP openers more selective pharmacologic agents. When the idea of testing K ATP openers in models of myocardial in isolated heart models from several species such as rats, rabbits, ferrets, and guinea-pigs. [44] [45] [46] [47] [48] The ischemia was suggested, we had to decide upon the best initial model to test these compounds. While profile of action of these compounds was similar and in general the cardioprotective concentrations these agents opened cardiac K ATP , they were more potent as vasodilators and we realized that inof these compounds were between 300 n and 10 . The cardioprotective effects observed for terpretation of the data from systemically treated animals could be difficult. We therefore determined K ATP openers have been observed as increased postischemic functional recovery, increased time to electhe effect of K ATP openers in an isolated rat heart model of ischemia and reperfusion in which direct trical uncoupling, and improved energy status, and reduced necrosis (enzymatic and histologically decardioprotective activity could be ascertained. We first tested pinacidil and cromakalim and found them termined). 35, 46, 48, 49 The study by Tan et al. 48 showed that guinea-pig papillary muscles had significantly both to protect isolated rat hearts subjected to 25 min global ischemia followed by 30 min reperfusion. 39 increased times to electrical uncoupling during hypoxia suggesting protection of gap junctions. Recent Protection was denoted by increased time to ischemic contracture, improved post-ischemic recovery of constudies from Ganote's laboratory have shown K ATP openers to protect hypoxic/reperfused rabbit venttractile function, reduced reperfusion contracture, and improved reperfusion flow. Figure 3 shows the ricular myocytes. 50 This study showed that at least some of the cardioprotective effects of K ATP openers Most of the studies aimed at elucidating the mechanism of action of preconditioning have used are exerted at the level of myocytes. Liang 51 has also shown K ATP openers to protect isolated chick a pharmacologic approach. This has led to a bewildering array of suggested receptors, signaling myocytes. K ATP openers also appear to have some efficacy in human tissue based on studies by pathways and metabolic mechanisms. [61] [62] [63] The multiplicity of biochemical systems involved with preSpeechly-Dick et al. 52 These investigators showed that cromakalim protected hypoxic/reoxygenated conditioning makes it difficult to understand how these various pathways fit together. human atrial trabecula, suggesting K ATP to be a clinically relevant pharmacologic target.
A useful organization of these findings divides the process into three components. 64, 65 (1) Triggers are Results with K ATP openers in models of myocardial ischemia in vivo have been somewhat more variable.
metabolites and receptor agonists that are released locally during the preconditioning ischemia. These This may be due to the fact that most of the K ATP openers used in these studies were not selective for include adenosine, acetylcholine, bradykinin, catecholamines, angiotensin II, and opioids. Receptor the heart and such activities (including hypotension) could have clouded interpretation of the activation triggers a cascade that ultimately activates mediators of preconditioning. (2) Mediators data. Nevertheless, there have also been numerous in vivo studies showing K ATP openers to be carinclude, most notably, protein kinase C, 14,66,67 but other kinases may also participate, including tyrosdioprotective. Early into our investigations, we found it difficult to achieve cardioprotection in vivo ine protein kinase 68 and mitogen-activated protein kinases. 69 There is evidence that a threshold quantwith K ATP openers when given systemically because of profound hypotension. Therefore, we found it ity of various triggers must be achieved in order for protein kinase C activation to be sufficient for necessary to administer the K ATP openers directly into the coronary arteries of dogs in order to observe cardioprotection. 64 The proteins that are phosphorylated have not been identified, but they precardioprotection. We found that both cromakalim and pinacidil significantly reduced infarct size in sumably reside within the final common pathway of protection and may include the end effector dogs. 40 Gross's laboratory showed that aprikalim could be given systemically in dogs and a reduction itself. (3) The end effector of preconditioning is also unknown, but there is a general consensus that in post-ischemic stunning observed, a result that was confirmed by our laboratory using cromakalim this may be the K ATP channel. In view of the results of Garlid et al., 37 mitoK ATP may play this role or may (except it was given into the coronary arterial circulation). 16, 53 Later studies by several laboratories at least be downstream of the previously mentioned mediators (it is currently unknown how mitoK ATP have shown K ATP openers to reduce infarct size in diverse species such as dogs, pigs, and rabbits. [54] [55] [56] [57] affects protection). In keeping with the scope of this review, we will limit further discussion to aspects It should be stated that several investigators have shown K ATP openers not to protect ischemic myoinvolving K ATP . The studies showing K ATP openers to mimic precardium in vivo and it is presently still difficult to reconcile these results. 58, 59 conditioning, which have already been described, are consistent with the notion that K ATP is crucial to preconditioning, but does not prove it. Further proof required the use of pharmacologic blockers
Role of K ATP in Preconditioning
of this channel. Before describing some of this work, it is worthwhile to point out one interesting study Endogenous protective mechanisms exist in many tissue types. Murry et al. 60 described a phenomenon showing a role for K ATP in preconditioning using an agonist. Yao and Gross 70 showed that the K ATP in hearts in which a short bout of ischemia will protect a heart from a subsequent ischemic episode opener, bimakalim, significantly lowered the threshold for preconditioning in a canine model of inof more prolonged duration. Preconditioning exists in many mammalian species and is found by nearly farction. This was done using a subthreshold preconditioning protocol combined with a suball investigators. It is not known whether this protective effect evolved specifically to increase rethreshold dose of bimakalim. This clever study strongly suggested that K ATP openers protect ischsistance to ischemia, or whether protection is a beneficial consequence of triggering a normal emic tissue in a manner which is similar to preconditioning. physiological response. While all investigators agree on the profound protection conferred by preGross's laboratory was the first to demonstrate that K ATP blockers abolish preconditioning using conditioning, there is less agreement on the molecular mechanism of protection.
glyburide in a canine model. 71 The structurally distinct blocker 5-HD was also shown to abolish have suggested that K ATP may be involved with activation of adenosine A 1 receptors. It has been preconditioning in a similar model. 72 K ATP blockers have been shown to abolish preconditioning in suggested that K ATP openers are protecting ischemic myocardium by increasing adenosine production rabbits, rats, pigs, and man. 73 The ability of K ATP blockers to abolish preconditioning in rats has been secondary to activation of ectosolic 5′-nucleotidase. 84 A study in hypoxic rabbit ventricular variable and may be model dependent. Thus, neither 5-HD or glyburide abolished preconditioning in myocytes showed that the K ATP opener pinacidil was protective and this effect was abolished by the isolated rat heart; 73 however, recent studies showed K ATP blockers to abolish preconditioning in rat hearts adenosine receptor antagonists SPT and DPCPX. 50 A recent collaborative study between our group in vivo. 74, 75 In addition to animal studies, preconditioning has also been shown to exist in human and Grosss group showed that the protective effect of bimakalim in dogs was not abolished by DPCPX, tissue. Tomai et al. 76 showed that glyburide abolished preconditioning in human subjects. They suggesting that this "reverse" pathway is not operative in this model. 85 It is difficult to reconcile were preconditioned with short periods of ischemia using coronary balloon occlusion and severity of these differences at the present time.
If one assumes that adenosine receptor activation ischemia was deteremined using ST-segment shifts and severity of chest pain. Glyburide abolished this is "upstream" of K ATP activation during preconditioning, then it becomes important to deterprotective effect. These results were confirmed by Yellon's group, showing that human atrial tramine the signaling pathway linking the two systems. Adenosine A 1 receptor stimulation inhibits belcula could be preconditioned with short durations of hypoxia and that glyburide abolished this PKA and can activate PKC, both of which are known to be involved with K ATP gating. PKC acprotective effect. 52 It was of great interest that blockers of adenosine tivation seems to be involved in the mechanism of preconditioning in several species. PKC has been A 1 receptors and K ATP completely abolished preconditioning in similar animal models, when given shown to be involved with activation of sarcolemmal K ATP in patch clamp studies and PKC alone. It was difficult to reconcile these results unless these two systems were linked. Studies by activation protects ischemic myocardium in a glyburide-reversible manner. 29,52 PKC activation appears Kirsch et al. 4 in neonatal rat cardiac myocytes, showed that adenosine A 1 receptor activation also to phosphorylate a protein associated with K ATP , resulting in activation. It should be remembered activated K ATP through a G i coupled pathway. This study prompted us to determine the effect of glybthat the work relating potassium currents to PKC activation was done using sarcolemmal channels, uride on the cardioprotective effect of an adenosine A 1 receptor agonist, R-PIA. 77 We found that R-PIA and the relevance to the pertinent K ATP (mitochondrial?) is not presently clear. This will be disreduced infarct size in dogs and this effect was completely abolished by glyburide, suggesting adcussed in more detail later in this review. Finally, it is constructive to review briefly the enosine receptor activation to be "upstream" of K ATP activation. Similar studies were performed in pigs phenomenon of calcium preconditioning as described by Meldrum et al. 86, 87 and Miyawaki and showing 5-HD to abolish the protective effect of R-PIA. 78 The cardioprotective effects of adenosine Ashraf. 88, 89 In calcium preconditioning, a transient increase in intracellular calcium preconditioned rat have also been shown to be abolished by glyburide in several species.
79, 80 A recent study by Cleveland et heart against subsequent global ischemia, and this cardioprotection is associated with activation of al. 81 showed that adenosine could protect hypoxic/ reoxygenated human atrial trabecula and this effect protein kinase C. 86, 87, 90 In a careful study, Kouchi et al. 91 have shown K ATP to be a common target of was abolished by glyburide, suggesting this pathway to be operative in man. Interestingly, rat both ischemic and calcium preconditioning. Significantly, these authors showed that glyburide cerebral preconditioning was abolished by glyburide, 82 suggesting that this phenomenon is imblocked cardioprotection when administered 30 min before preconditioning but not when given portant in tissues other than heart. In this study, K ATP -mediated protection appeared to be preceded 5 min after preconditioning. These data are consistent with data reported previously in rats in and activated by adenosine A 1 receptor stimulation. A recent study by Ford et al. 83 showed that glyburide vivo. 92 The time dependence of glyburide blockade is consistent with the necessity to interact with an failed to abolish the protective effects of adenosine A 1 activation, although rat hearts may not be intracellular receptor, and emphasizes the importance of consdiering pharmacokinetics in such studpredictive of human tissue in this regard.
It is important to note that several investigators ies. ers. 97 Therefore, it appears as if most of the protective Two structurally distinct K ATP blockers, sodium 5-effects of K ATP openers occurs during ischemia, alhydroxydecanoate (5-HD) and glyburide were availthough some effects on reperfusion injury cannot able to further test the hypothesis that K ATP are be ruled out at the present time. important in mediating cardioprotection. Both Most K ATP openers are potent vasodilators and agents have been universally shown to abolish one possible mechanism for their protection was the cardioprotective effects of K ATP openers. 46 In coronary dilation, although this was thought to be addition, glyburide abolishes the pre-ischemic corunlikely. We showed that the protective effect of onary vasodilator effects of K ATP openers.
93 5-HD aprikalim was still observed even when coronary seems to be more selective and was originally flow was held constant in isolated rat hearts. 42 In thought to be specific for inhibiting the carvivo, several investigators showed that cardioprotective effects of K ATP openers and will not dioprotective doses of K ATP openers had no effect on abolish the effects of K ATP openers on non-ischemic coronary collateral blood flow, although they did cardiac and vascular tissue. 93 This will be discussed enhance reperfusion blood flow. 40, 54 The studies in more detail later. It is important to note that most by Armstrong et al. 50 showed pinacidil to protect investigators find that K ATP blockers (in reasonable isolated cardiac myocytes, which further shows a doses) do not further aggravate severity of ischemia, lack of importance of coronary flow changes. 98 showed K ATP activation is important, it is still unknown how K ATP openers to significantly conserve myocardial this could confer physiologic protection of ischemic ATP during ischemia. The degree of ATP conor reperfused myocardium. We will now discuss servation was comparable to that seen for calcium what is known about the physiologic mechanism channel blockers, although K ATP openers caused of action for cardioprotection for this class of agents.
little negative inotropic effects, at least in our hands. One question that arose was whether K ATP openers K ATP openers also enhanced post-ischemic recovery protected during ischemia per se or during reof ATP 99 suggesting that mitochondria are protected perfusion. An increase in the time to onset of and electron microscopy showed this to be true. 49 contracture during ischemia strongly suggested an Efficiency of oxygen utilization was significantly effect of K ATP openers during ischemia (see Fig. enhanced by K ATP openers, indicating that ischemic/ 3). 46 Pharmacologic studies have shown that K ATP reperfusion uncoupling of mitochondria is inopeners work best when given well before the hibited.
99
ischemic event, although this does not prove an The results showing little cardiodepressant effects effect during ischemia. 40 In our hands, most K ATP for K ATP openers, while they conserved ischemic openers have weak (or non-existent) protective effects when given during reperfusion, but it is pos-ATP was intriguing as significant APD shortening should cause reduced contractile function. This nel patches or by measuring whole myocyte K + currents. 47 In guinea-pig papillary muscles, BMSsuggested the possibility that K ATP openers were not working through a cardioplegic mechanism and 180448 was devoid of APD shortening activity (intracellular recordings) at concentrations which possibly not through sarcolemmal channels. A study by Pignac et al. 100 showed that aprikalim exerted significant cardioprotective effects, although the cardioprotective effects were abolished exerted an additional protective effect over that afforded by depolarizing cardioplegia in isolated by glyburide or 5-HD. 104 These data suggested that compounds which are selective for the cardiorabbit hearts. We confirmed this in isolated rat hearts and found the K ATP openers cromakalim and protective site could be developed, although the nature of this site is still not clear. It is evident BMS-180448 to exert additive protective effects over hypothermic or normothermic St Thomas' that some degree of selectivity can be observed for blockers as well. of K ATP openers and had no effect on the protective activity of the cardioplegic solution alone. These It is also of interest that 5-HD is incapable of blocking the vasodilator effects of K ATP openers. results suggest that K ATP openers work via a mechanism distinct from cardioplegia and since these As discussed earlier, K ATP appear to be involved in mediation of preconditioning and the potential hearts are arrested in systole, the hearts were electrically quiescent and therefore APD shortening relevance of sarcolemmal K ATP has also been questioned for this phenomenon. Studies have shown was not likely to be an important mechanism of action for these agents.
preconditioning to cause APD shortening, both during and after preconditioning in some studies, alThe suggestion of a lack of importance of APD shortening was disquieting as it suggested a lack though this does not definitively prove sarcolemmal channels to be essential for preconditioning. 56, 105 of importance of sarcolemmal K + currents in mediating the cardioprotective effects of K ATP openers.
Recent studies by Much-Ellingsen et al. 106 showed that dofetilide has no effect on preconditioning in At approximately the same time as the cardioplegic studies were published by Pignac et al., 100 Gross rabbits. These studies suggest that preconditioning, like pharmacologic K ATP opening, does not depend and co-workers found that a dose of bimakalim could be used which reduced infarct size in dogs, on activation of sarcolemmal K + currents and an intracellular site of action may be relevant. A recent but was without effect on epicardial monophasic APD. 101 We confirmed these findings by pharstudy by Hamada et al. 103 confirmed that preconditioning in dogs is independent of APD shortmacologically blocking the APD shortening activity of cromakalim (epicardial monophasic APD) with ening, further suggesting sarcolemmal K ATP activation is not the primary or sole mediator of the delayed rectifier blocker dofetilide and found cromakalim to nevertheless reduce infarct size. 102 preconditioning. A recent study by Linz et al. 107 suggested that a pharmacologic blocker which is A recent study by Hamada et al. 103 showed that APD shortening is not a prerequisite for cardioprotection selective for sarcolemmal K ATP did not abolish preconditioning while glyburide completely abolished induced by pinacidil in a canine model of infarction in anesthetized dogs. While these studies were well preconditioning. The question is whether sarcolemmal K ATP are executed and represented early evidence for a separation of APD shortening and cardioprotection, critical for the protective effect of K ATP activation (both pharmacologic or preconditioning) or measurement of epicardial monophasic action potentials are a relatively crude technique for measwhether intracellular K ATP may be involved. Taken together, the data described above show a poor uring changes in APD, especially in the critical areas of the ischemic myocardium (below the epicardial correlation between sarcolemmal K + current activation and cardioprotection for K ATP openers. This surface). It therefore became necessary to undertake more detailed studies using patch clamp and well is perplexing given the near universal finding of cardioprotection for structurally distinct K ATP openas intracellular recording techniques.
We have developed pyranyl cyanoguanidine anaers and their inhibition by K ATP blockers. It is certainly possible that K ATP are not involved with logs which retain the glyburide-reversible cardioprotective activity of cromakalim while being cardioprotection, but this seems improbable. It is also possible that K ATP openers may interact with relatively devoid of vasodilator activity. 36 Interestingly, we also found that many of these agents, sarcolemmal K ATP in a manner we do not understand and will affect cardioprotection even without acincluding BMS-180448, were poor at opening cardiac sarcolemmal K ATP as measured in single chantivation of a potassium current. We were hampered by a lack of knowledge of the relevant carreconstitution of a highly purified mitoK ATP . 117 Although it possesses unique regulatory properties, midioprotective binding site for the pharmaologic openers of K ATP . Binding sites for K ATP openers have toK ATP is regulated by every ligand that regulates plasma membrane K ATP channels; consequently, we been found in cardiac, smooth muscle and skeletal muscle cell membranes, but the relationship of these infer that it belongs to the same gene family. The sole known function of the mitochondrial sites to ischemia are not clear. 108, 109 It has also been suggested that K ATP openers may interact with an K + cycle is to regulate matrix volume. 114 The effect of net K + movement causes only minor perintracellular K ATP . We hypothesized several years ago that mitochondrial K ATP might be the carturbations of matrix pH, because of accompanying movement of weak acids; of matrix K + condioprotective site of action for K ATP openers. In the next section the possible importance of mitocentration, because of accompanying movement of osmotically obligated water; or of (the electrical chondrial K ATP in mediating cardioprotection will be discussed in detail.
potential difference), because the fluxes are low relative to proton pumping by the electron transport chain. Thus, the K 116 with mitoK ATP .
The high affinity of mitoK ATP for ATP raised the reported evidence from patch clamp studies of fused mitoplasts at the same time that we began describing conundrum of how this channel can be opened under physiological conditions. We hypothesized that which would normally be present during in vivo experiments. We infer from these and other exendogenous activators overcome the high affinity for ATP, and we confirmed this hypothesis by showing periments that binding of glyburide and 5-HD to mitoSUR is conformation-dependent and that mithat guanine nucleotides reverse the inhibition by ATP, ADP or palmitoyl CoA in both mitochondria toSUR conformation is changed by binding of the other ligands. When the appropriate ligands (e.g. and proteoliposomes. 122 Guanine nucleotides are competitive with ATP. GTP appears to react with a Mg
2+
, ATP, or cromakalim) are present in the assay medium, glyburide and 5-HD are potent, specific high affinity (0.2 ) and a low affinity (15-20 ) site, whereas GDP appears to react with two low blockers of K + flux in respiring mitochondria, with K i values of about 1  and 50 , repectively. 120 affinity sites (20 ). ATP is unable to inhibit in the presence of physiological GTP concentrations; for example, 20  GTP increased the K 1/2 for ATP inhibition from 21  to 6 m. On the other hand, Molecular structure of mitoK ATP the K 1/2 for GTP activation of palmitoyl CoA inhibition is in the physiological range. Our present thinking
We have tentatively identified two components of mitoK ATP -a 55 kD channel protein and a 63 kD is that ATP does not regulate mitoK ATP in vivo, and that the open/closed state of the channel is determined by sulfonylurea receptor (SUR), based on its labeling with bodipy-glyburide (unpublished observation). the relative occupancy of the sites by GTP or longchain acyl CoA esters. We speculate that the two
Thus, it appears that mitoK ATP has a heteromultimeric structure akin to that of plasma membinding sites correspond to the nucleotide binding folds on mitoSUR.
brane K ATP . Neither subunit has been cloned, but this is the focus of active research. In order to understand the role of mitoK ATP in cellular bioenergetics, it is necessary to know where An interesting observation was made by Suzuki et al., 124 who showed that mitochondria are imits regulatory sites are located. Do they face the matrix, as suggested by Inoue et al., 116 or do they munostained with antibodies to KIR6.1, an inward rectifying K + channel that is known to be expressed face the cytosol? Do they all coexist on the same pole of the protein? Experiments in proteoliposomes in plasma membranes. Preliminary data show that these antibodies do indeed react with a mitoand mitochondria demonstrate that the mitoK ATP regulatory sites for Mg 2+ , ATP, GTP and palmitoyl chondrial protein; however, they do not react with any protein in the reconstitutively active purified CoA face the cytosol, or more precisely, the intermembrane space. 118 fraction of mitoK ATP . In view of the fact that the antibodies were raised to a 12 amino acid fragment of KIR6.1, it may be that they recognize a non-K ATP protein with homology in a limited domain. Pharmacological modulators of mitoK ATP K ATP openers reverse inhibition of mitoK ATP by ATP, ADP, and palmitoyl CoA with K 1/2 values that are well within the ranges observed for plasma memDifferential pharmacology of cardiac sarcolemmal and mitochondrial K ATP brane K ATP channels from various tissues.
123 Thus, the K 1/2 values were 1  and 0.4  for croWe measured K + fluxes in liposomes containing makalim and diazoxide, respectively.
121 Similar values were obtained in intact mitochondria and in purified K ATP to address the question of receptor subtypes within the cardiac myocyte. These proliposomes containing reconstituted mitoK ATP .
We have recently succeeded in removing a major tocols have several advantages, including the ability to compare proteins from different sources using barrier to understanding the pharmacology of mitoK ATP inhibitors. 120 Under most conditions, glybidentical assay conditions. Sarcolemmal K ATP and cardiac mitoK ATP were purified from beef heart and uride and 5-HD are ineffective in intact, respiring mitochondria. 119 We have now shown that this assayed for flux. The two preparations shared many properties in common. Flux was inhibited by ATP, phenomenon reflects a particular characteristic of mitoK ATP and is due entirely to the conditions of and this inhibition was reversed by cromakalim in both preparations. The resulting pharmacological the experiment. Thus, in the absence of other ligands, the channel is open, but not inhibitable by open state was inhibited by glyburide in both preparations. glyburide or 5-HD. Sensitivity to inhibitors requries the simultaneous presence of Mg 2+ , ATP, and an 5-HD exhibited a profoundly differet pharmacology in the two preparations. 5-HD always opener which may be GTP or a pharmacologic opener. Of course, these ligands are precisely those inhibited mitoK ATP under appropiate conditions, but never inhibited sarcolemmal K ATP under any conAre mitoK ATP the sites of cardioprotection? ditions. This failure of 5-HD to block sarcolemmal K ATP is consistent with previous observations. 93 It A number of studies have demonstrated that cardiac sarcolemmal K ATP are relatively insensitive to diazoshould be pointed out that the blocking activity of 5-HD in sarcolemmal channels has not been studied xide, 23,121 whereas mitoK ATP are sensitive in the micromolar range. 121 Accordingly, we studied the in any detail.
Diazoxide also exhibited a pronounced differential effect of diazoxide in an isolated rat heart model of ischemia and reperfusion. We observed conpharmacology between sarcolemmal K ATP and mitoK ATP , as shown in Figure 4 . In this experiment, centration-dependent cardioprotection in the low micromolar range with no correlation to APD shortdiazoxide was 1000-times more potent in opening mitoK ATP than in opening sarcolemmal K ATP . We ening (Figs 3, 5 and 6). 37 While diazoxide had little effect on APD, cromakalim did shorten APD normally observe K 1/2 values for opening by diazoxide of 0.5-0.8  with mitoK ATP and 0.8-1.0 m markedly within its cardioprotective range. Therefore, diazoxide and cromakalim were found to bewith sarcolemmal K ATP . have similarly in terms cardioprotection and in preconditioning, PKC activity and mitoK ATP . 126 With regard to preconditioning, it is important to note opening mitoK ATP . They differed markedly in their effects on APD and on the opening of reconstituted that 5-HD also completely abolishes the protective effect of this phenomenon, further suggesting an sarcolemmal K ATP . Both glyburide and 5-HD completely abolished the protective effects of diazoxide involvement of mitoK ATP . (Fig. 6) . These results appear to exclude a role for sarcolemmal K ATP in ischemic protection.
These differential effects of 5-HD and diazoxide
K ATP : Future Directions
are consistent with our hypothesis that mitoK ATP is the receptor for cardioprotection by K ATP openers Recent years have seen an explosive growth in interest in the role of K ATP in the pathogenesis of and for 5-HD blockade of pharmacolgical protection or preconditioning. 37 The caveat, at present, is that myocardial ischemia. The great majority of investigators find that K ATP openers exert carthe existence of a third myocardial K ATP subtype, with receptor properties similar to mitoK ATP , has dioprotective effects in numerous models of myocardial ischemia. This protection appears to be not yet been ruled out.
Liu et al. 125 have recently confirmed diazoxide related to energy sparing effects which are not due to reductions in cardiac work. Overall, K ATP openers cardioprotection in the isolated rabbit myocyte model and these authors support the hypothesis have an excellent cardioprotective profile which is further enhanced by the possibility that they mimic that mitoK ATP mediates cardioprotection with pharmacologic K ATP openers. Additional experiments on an endogenous protective mechanism. While an important role for K ATP in ischemia seems to have the same model provide evidence that protein kinase C activation potentiates diazoxide opening of mimet with general agreement, there is much that is still unknown. toK ATP , providing a partial linkage between ischemic There are two major mechanistic issues: current their use. Agents have been reported which retain cardioprotective effects while being devoid of vasoinformation suggests that mitoK ATP may be the end effectors of cardioprotection, but further work dilator activity, 36 suggesting that tissue selectivity is possible. In this series are found many agents is essential to assure ourselves that mitoK ATP is indeed the protective site of action of both that are devoid of vasodilator and APD shortening activities, making them more selective for treating pharmacologic agonists and preconditioning. Secondly, it is not clear how opening mitoK ATP will ischemia without the potential for increasing reentrant arrhythmias, as might be seen for agents exert ATP-sparing effects. It is critical to determine the molecular mechanism of cardioprotection proactivating sarcolemmal currents. 127 The results of studies designed to assess pro-arrhythmic potential vided by activation of K ATP . Only when this mechanism is understood can we begin to unof non-selective K ATP openers have been variable, [128] [129] [130] [131] [132] [133] but nevertheless any drug discovery effort derstand the complex signaling pathways important in preconditioning. Understanding this should take this potential toxicity seriously and attempt to minimize the effects of these agents on mechanism may also be important in developing novel therapeutics for treating myocardial isch-APD or refractoriness. Despite the absence of APD shortening or vasodilator activity, the cardioemia.
The therapeutic issue is that existing K ATP openers protective effects of the selective compounds described by Atwal et al. 36 are abolished by glyburide may not be optimal for treating acute myocardial ischemia. Most K ATP openers have little tissue seand 5-HD. It is presently unknown whether these compounds are selective for mitoK ATP . Although lectivity, and they also have the propensity to cause hypotension and APD shortening, which may limit these agents are more selective for cardioprotection, 
